Physician profile
Robert N Stein
NPI 1245230309
$20,823.28
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13,649.30 | 2019 | |
| Pfizer INC. | $6,790.12 | 2019 | |
| Janssen Biotech, INC. | $57.67 | 2019 | |
| Astellas Pharma US INC | $38.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.72 | 2019 | |
| Novo Nordisk INC | $34.47 | 2019 | |
| Genzyme Corporation | $31.91 | 2019 | |
| Rigel Pharmaceuticals, INC. | $24.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.84 | 2019 | |
| Exelixis INC. | $21.22 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $20.09 | 2019 | |
| Secura Bio, INC. | $19.03 | 2019 | |
| Merck Sharp & Dohme LLC | $18.46 | 2019 | |
| Eisai INC. | $17.67 | 2019 | |
| Verastem, INC. | $15.29 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.